Advertent Biotherapeutics
Advertent Biotherapeutics is dedicated to improving lives by developing novel therapies that restore health after musculoskeletal injuries. Their approach leverages the body's own growth factors to stimulate regeneration and prevent tissue degeneration, aiming to accelerate healing and enhance patient outcomes. The company focuses on targeting the TGF-β superfamily to develop precision therapies for the 21st century.
Industries
Nr. of Employees
small (1-50)
Advertent Biotherapeutics
East Lansing, Michigan, United States, North America
Products
Pipeline therapeutic candidate targeting growth‑factor pathways for musculoskeletal regeneration
A lead drug candidate program that modulates growth‑factor signaling to promote regeneration and prevent degeneration of musculoskeletal tissues; intended to improve recovery after soft tissue injury and outcomes in chronic neuromuscular conditions.
Pipeline therapeutic candidate targeting growth‑factor pathways for musculoskeletal regeneration
A lead drug candidate program that modulates growth‑factor signaling to promote regeneration and prevent degeneration of musculoskeletal tissues; intended to improve recovery after soft tissue injury and outcomes in chronic neuromuscular conditions.
Expertise Areas
- Musculoskeletal therapeutic development
- Growth factor (TGF‑β family) signaling biology
- Preclinical muscle regeneration research
- Molecular biology and biochemistry
Key Technologies
- Growth factor signaling modulation (TGF‑β family)
- Molecular biology techniques
- Biochemical assays for signaling pathways
- Preclinical in vivo muscle regeneration models
News & Updates
We are happy to welcome Dr. Philippe Clavel, Ph.D. to Advertent’s Advisory Board. Dr. Clavel will assist Advertent in developing our lead drug candidate for commercialization.
We are happy to welcome Dr. Philippe Clavel, Ph.D. to Advertent’s Advisory Board. Dr. Clavel will assist Advertent in developing our lead drug candidate for commercialization.